2029, Competition, Food and Drug Administration and Sales

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2029

Competition

Food and Drug Administration

Sales

NICE recommends AbbVie’s/J&J’s Imbruvica for combo use in untreated CLL

Pharmaceutical Technology

APRIL 24, 2023

While Imbruvica maintained a previously strong position on the market, competition has chipped away at the inhibitor’s market share. Brukinsa was approved by the US Food and Drug Administration (FDA) in CLL in January 2023. billion in 2029, while Calquence is expected to make $5.31 While Imbruvica sales were $3.78

Food and Drug Administration

Food and Drug Administration Side effects Sales Food

Intercept receives orphan drug designation for liver disease combo therapy

Pharmaceutical Technology

MAY 17, 2023

The US Food and Drug Administration (FDA) has awarded an orphan drug designation to Intercept Pharmaceuticals’ fixed-dose combination of obeticholic acid and bezafibrate for the treatment of primary biliary cholangitis. billion in 2029. GlobalData is the parent company of Pharmaceutical Technology.

Food and Drug Administration

Food and Drug Administration FDA Pharmaceutical Prospecting

Pharma Rep Focus

NICE recommends AbbVie’s/J&J’s Imbruvica for combo use in untreated CLL

Intercept receives orphan drug designation for liver disease combo therapy

Stay Connected